Biomarkers and Case Reports


Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo a rigorous assessment before and after licensure to minimize safety concerns. Potential safety concerns should be identified as early as possible during the development of vaccines and biologicals to minimize investment risk. State-of-the-art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions.


    Related Conference of Biomarkers and Case Reports

    November 26-27, 2021

    33rd Annual Congress on Immunology and Vaccinations

    Vancouver, Canada
    December 01-02, 2021

    41st Global Summit and Expo on Vaccines & Immunology

    Frankfurt, Germany

    Biomarkers and Case Reports Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in